Authors
Heather C Kaplan, Lisa Opipari-Arrigan, Jiabei Yang, Christopher H Schmid, Christine L Schuler, Shehzad A Saeed, Kimberly L Braly, Fandi Chang, Lauren Murphy, Cassandra M Dodds, Mason Nuding, Hao Liu, Sheri Pilley, Julie Stone, Gisele Woodward, Nancy Yokois, Alka Goyal, Dale Lee, Ann Ming Yeh, Peter Lee, Benjamin D Gold, Zarela Molle-Rios, R Jeff Zwiener, Sabina Ali, Mallory Chavannes, Tiffany Linville, Ashish Patel, Travis Ayers, Mikelle Bassett, Brendan Boyle, Pablo Palomo, Sofia Verstraete, Jill Dorsey, Jess L Kaplan, Steven J Steiner, Kaylie Nguyen, Jennifer Burgis, David L Suskind
Publication date
2022/6/1
Journal
Official journal of the American College of Gastroenterology| ACG
Volume
117
Issue
6
Pages
902-917
Publisher
LWW
Description
METHODS:
Across 19 sites, we recruited patients aged 7–18 years with IBD and active inflammation. Following a 2-week baseline (UD), patients were randomized to 1 of 2 sequences of 4 alternating 8-week SCD and MSCD periods. Outcomes included fecal calprotectin and patient-reported symptoms. We report posterior probabilities from Bayesian models comparing diets.
RESULTS:
Twenty-one (39%) participants completed the trial, 9 (17%) completed a single crossover, and 24 (44%) withdrew. Withdrawal or early completion occurred commonly (lack of response [n= 11], adverse events [n= 11], and not desiring to continue [n= 6]). SCD and MSCD performed similarly for most individuals. On average, there was< 1% probability of a clinically meaningful difference in IBD symptoms between SCD and MSCD. The average treatment difference was− 0.3 (95% credible interval− 1.2, 0.75). There was no significant …
Total citations
2022202320242112
Scholar articles
HC Kaplan, L Opipari-Arrigan, J Yang, CH Schmid… - Official journal of the American College of …, 2022